Fortitude Family Office’s ProKidney PROK Stock Holding History

Fortitude Family Office’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-490	Closed	-$290	–	2102
2025 Q2	$290	Buy	+490	New	+$382	﹤0.01%	1928

Other funds holding PROK

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fortitude Family Office's PROK Position: Q3 2025 in Review

Fortitude Family Office sold out of ProKidney (PROK) in Q3 2025, closing a stake of 490 shares — an estimated $290 sold.

Fortitude Family Office first reported a position in PROK in Q2 2025 and held it in 1 quarter. The position peaked at $290 in Q2 2025. 56 funds tracked by Wall St. Rank hold PROK as of Q3 2025.

Fortitude Family Office reported no remaining ProKidney position as of Q3 2025 after selling out during the quarter.
Fortitude Family Office sold 490 ProKidney shares in Q3 2025, an estimated $290.
Fortitude Family Office first reported a position in ProKidney in Q2 2025 and held it in 1 quarter.
Fortitude Family Office's ProKidney position peaked at $290 in Q2 2025.
56 funds tracked by Wall St. Rank held ProKidney as of Q3 2025.

Based on Fortitude Family Office's 13F filing for Q3 2025, filed 17 Oct 2025.